Prostate Cancer and NSAIDs

Summary: Use of Non-Steroidal Anti-Inflammatory Drugs and risk of Prostate cancer in montreal, CANADA

Mansure, JJ; Ramanakumar AV; Aprikian, AG; Kassouf, W; Franco, EL;  Parent, M-E

At least 20% of all cancers, including prostate cancer, develop because of chronic or recurring inflammation. As a result, researchers have been testing the logical guess that non-steroidal anti-inflammatory drugs (NSAIDs)* might contribute to prostate cancer prevention.  However, the evidence to date remains limited and results are inconsistent. This group of researchers have investigated the association between use of NSAIDs, daily low dose of acetylsalicyclic acid (ASA)**, and the risk of developing prostate cancer in the context of a large population-based case-control study.

They found that long-term use (defined as over 10 years) of NSAIDs slightly increases the risk of prostate cancer, quite contrary to the initial prediction but similar to other recent data. It did not make a difference whether the participants were currently using NSAIDs, or if the use took place in the past. The researchers also discovered that daily low dose use of ASA over 5 years increased prostate cancer risk, while shorter use showed a protective effect. Usage did not affect the aggressiveness of prostate cancer.

For the first time in a prostate cancer study, lifetime use of NSAIDs was assessed in terms of both prescribed and over-the-counter medication through in-person interviews.The participants were asked about their medical history, and if deemed an NSAID user, about the age when each medication was started and ended, allowing for the possibility of interruptions. The same questions were asked about ASA use, if taken to prevent blood clots. The study design also addressed some flaws from past investigations: all prostate cases were confirmed; controls, who were from a highly screened population, reported no history of the disease; exposure was more certain; and more information on dose and duration of use was collected than had previously been the norm.

While there was a weak increase in risk if participants had ever used NSAIDs, variants in several inflammation genes should be examined in future studies to help clarify any initial associations between inflammation, non-steroidal inflammatory medications, and prostate cancer risk.


*NSAIDs are any of the following: Ibuprofen, Advil, Motrin, Nuprin, Novo-Profen, Naproxen, Naprosyn, Aleve, Anaprox, Aspirin, Anacin, Ascriptin, Bufferin, Entrophen, Ansaid, Froben, ApoDiclo, Artrotec, Novo-Difenac, Voltaren, Bextra, Celebrex, Mobicox, Vioxx, Indomethacin, Indocid, Indotec, Lodine, Ultradol, Surgam, or Tiafen.

**ASA can be in the forms of Asaphen, Aspirin, Entrophen, or Novasen.